Safety and efficacy of topical formulations containing 0·5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study.

Masur, C; Soeberdt, M; Kilic, A; Knie, U; Abels, C

Masur, C; Soeberdt, M; Kilic, A; Knie, U; Abels, C.

Affiliation

Masur C; Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld, Germany.
Soeberdt M; Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld, Germany.
Kilic A; Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld, Germany.
Knie U; Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld, Germany.
Abels C; Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld, Germany.

Br J Dermatol ; 182(1): 229-231, 2020 01.

Article in En | MEDLINE | ID: mdl-31218668

Subject(s)

Glycopyrrolate; Hyperhidrosis; Axilla; Double-Blind Method; Glycopyrrolate/adverse effects; Humans; Hyperhidrosis/drug therapy; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Glycopyrrolate / Hyperhidrosis Type of study: Clinical_trials Limits: Humans Language: En Journal: Br J Dermatol Year: 2020 Type: Article Affiliation country: Germany

Fulltext

XML

PubMed Links

Search on Google